Artiva Biotherapeutics (ARTV) Total Liabilities (2023 - 2026)

Artiva Biotherapeutics (ARTV) has reported Total Liabilities for 4 consecutive years, with $18.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Liabilities fell 19.45% year-over-year to $18.1 million; the TTM figure through Mar 2026 stood at $18.1 million (down 19.45% YoY), while the FY2025 annual figure was $21.0 million, down 8.59% from the prior year.
• Total Liabilities retreated to $18.1 million in Q1 2026 per ARTV's latest filing, from $21.0 million in the prior quarter.
• Across five years, Total Liabilities topped out at $50.7 million in Q4 2023 and bottomed at $18.1 million in Q1 2026.
• Historically, Total Liabilities has averaged $27.8 million across 4 years, with a median of $22.5 million in 2025.
• On a YoY basis, Total Liabilities climbed as much as 8.59% in 2025 and fell as far as 59.78% in 2025.
• Artiva Biotherapeutics' Total Liabilities stood at $50.7 million in 2023, then tumbled by 54.77% to $22.9 million in 2024, then retreated by 8.59% to $21.0 million in 2025, then decreased by 13.65% to $18.1 million in 2026.
• Business Quant data shows ARTV's Total Liabilities at $18.1 million in Q1 2026, $21.0 million in Q4 2025, and $19.6 million in Q3 2025.